Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer (DAPROCA-1)

This study has been terminated.
(A consequence of the results of the ENTHUSE phase III study program)
Sponsor:
Collaborator:
Rigshospitalet, Denmark
Information provided by (Responsible Party):
Michael Borre, Aarhus University Hospital
ClinicalTrials.gov Identifier:
NCT01000948
First received: October 22, 2009
Last updated: January 7, 2014
Last verified: July 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2011
  Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)